Pharmacokinetics and Safety of Posaconazole Tablet in Participants at High Risk for Invasive Fungal Infections (MK-5592-065/P05615)

Phase 1

Completed

Conditions: Fungal Infections

Interventions: Drug: Posaconazole 200 mg
Drug: Posaconazole 300 mg

Registration Number: NCT01777763

Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary: The purpose of this study is to collect pharmacokinetic (PK) information related to how well posaconazole tablet is distributed in the body and to determine the safety of this new formulation. The study consists of a Phase 1B study that includes participants with neutropenia undergoing chemotherapy for acute myelogenous leukemia (AML) or myelodysplasia (MDS) and a Phase 3 study that includes participants who are undergoing chemotherapy for AML or MDS and participants who are recipients of allogeneic hematopoietic stem cell transplant (HSCT).

Detailed Description: Participants with a blood disease or cancer that can affect their infection-fighting white blood cells and those who have undergone a hematopoietic stem cell transplant (HSCT) and are receiving immunosuppressive therapy and have or are at risk of graft-vs-host disease (GVHD) are eligible for the study. These blood diseases and their treatments can weaken the immune system and may put individuals at high risk for a serious fungal infection of their internal organs or blood (invasive fungal infection). As these infections can be hard to detect early and can be life-threatening, many physicians believe that individuals diagnosed with these diseases should receive antifungal therapy to try to lower their risk of getting this type of infection.

Enrollment into this study will take place in several stages (parts). The determination of which part a participant will be in is based on which part is open at the site at the time of enrollment.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 230

Inclusion Criteria

Body weight >34 kg (75 lb) and of any race/ethnicity
Able to swallow oral tablets whole
Anticipated (likely to develop within 3-5 days) or documented neutropenia due to chemotherapy, chemotherapy for a new diagnosis of acute myelogenous leukemia (AML), or AML in first relapse; myelodysplastic syndromes (MDS) in transformation to AML; allogeneic hematopoietic stem cell transplant (HSCT) participants in the pre-engraftment period or in the post-engraftment period if they are receiving immunosuppressive therapy for graft versus host disease

Exclusion Criteria

Female must not be pregnant, must not intend to become pregnant

during the study, and must not be nursing

History of hypersensitivity to azoles
Moderate or severe liver dysfunction defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels greater than three times the upper limit of normal (ULN), AND a total bilirubin level greater than two times the ULN
Electrocardiogram (ECG) with corrected QTc interval greater than 500 msec
Posaconazole within 10 days before study enrollment
Receipt of systemic antifungal therapy within 30 days of study enrollment for reasons other than antifungal prophylaxis
Evidence of known or suspected invasive or systemic fungal infection at baseline
Known or suspected history of Gilbert's disease
Creatinine clearance levels below 30 mL/min

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Posaconazole 200 mg	Posaconazole 200 mg	Posaconazole 200 mg (two 100 mg tablets) twice daily (BID) on Day 1 followed by 200 mg (two 100 mg tablets) once daily (QD) for up to 28 days
Posaconazole 300 mg	Posaconazole 300 mg	Posaconazole 300 mg (three 100 mg tablets) BID on Day 1 followed by 300 mg (three 100 mg tablets) QD for up to 28 days

Primary Outcome Measures

Name	Time	Method
Average Concentration (Cavg) of Posaconazole Tablet	Predose on Day 1 up to 24 hours postdose on Day 8	Posaconazole steady-state concentrations of posaconazole in the plasma reached after regular and repeated dosing were used to estimate pharmacokinetic (PK) parameters for each participant where Cavg was defined as area under the plasma concentration versus time curve divided by the dosing interval. Blood samples for the assessment of Cavg were collected on Day 1 and Day 8 predose and then at specified time points up to 24 hours postdose.
Time to Maximum Concentration (Tmax) of Posaconazole Tablet	Predose on Day 1 up to 24 hours postdose on Day 8	Blood samples for the assessment of Tmax were collected on Day 1 and Day 8 predose and then at specified time points up to 24 hours postdose.
Minimum Concentration (Cmin) of Posaconazole Tablet	Predose on Day 1 up to 24 hours postdose on Day 8	Cmin was defined as posaconazole trough level immediately before a participant received the dose of posaconazole tablets on the specified day. Trough (Cmin) level blood samples for determination of posaconazole in plasma were collected for all participants on Day 1, Day 2, Day 3, and Day 8. On Day 1, the trough level sample was collected the before the first dose of study drug. On Day 2, trough samples were collected approximately 12 hours after the second dose of study drug was administered on Day 1. On all subsequent days, trough samples were collected approximately 24 hours following the previous day's dose of study drug.
Maximum Concentration (Cmax) of Posaconazole Tablet	Predose on Day 1 up to 24 hours postdose on Day 8	Blood samples for the assessment of Cmax were collected on Day 1 and Day 8 predose and then at specified time points up to 24 hours postdose.
Apparent Total Body Clearance (CL/F) for Posaconazole Tablet	Predose on Day 1 up to 24 hours postdose on Day 8	Blood samples for the assessment of CL/F, the rate at which posaconazole was removed from the body, were collected on Day 1 and Day 8 predose and then at specified time points up to 24 hours postdose.